Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q3 2024 (September 30)4holders −1
1new positions
2sold out
$0.92avg. 13F price*
At the end of Q3 2024, 4 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings, down 1 from Q2 2024. 1 opened new positions and 2 sold out. The largest holders were New York State Common Retirement Fund ($2.5M), Ewing Morris & Co. Investment Partners Ltd. ($2.3M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.1M).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2.3M |
| Exits | 2 | $579K |
All 13F filers, Q2 2024 → Q3 2024: 2,000,000 shares bought and 724,000 shares sold, net +1,276,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| New York State Common Retirement Fund | 0.00% | No change | 2,937,000 | $2.5M |
| Ewing Morris & Co. Investment Partners Ltd. | 1.10% | New | 2,000,000 | $2.3M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 2,500,000 | $2.1M |
| Sei Investments Co. | 0.00% | No change | 156,000 | $130K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.